RxDoctor Payments Data

Robin Wind, MD

Internal Medicine · Winnetka, ILNPI 1265427546

Payments from drug & device makers

$779in general payments, 2019–2025

Across 36 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$129
  • Lilly USA, LLC$120
  • Sanofi Pasteur Inc.$61
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • Currax Pharmaceuticals LLC$53
  • Eisai Inc.$52
  • plus $303 from 11 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$147,555
Medicare patients
137
Services billed
1,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$11,199
JanuviaSitagliptin Phosphate25$7,283
MyrbetriqMirabegron25$5,869
Atorvastatin Calcium218$2,318
Levothyroxine Sodium142$1,614
Rosuvastatin Calcium97$1,357
Metoprolol Succinate62$886
Ramipril158$864
Amlodipine Besylate116$852
Escitalopram Oxalate73$831
Albuterol Sulfate HfaAlbuterol Sulfate22$799
Simvastatin52$767
Pantoprazole Sodium27$556
Fluticasone Propionate21$553
Ezetimibe30$553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$120$11,19911 claims
Astellas Pharma US IncMyrbetriq$12$5,86925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Winnetka

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →